Upcoming clinical-trial readout dates for mid- and large-cap
biotech companies, plus the SEC filings where results get announced. Free to
read, no account needed. Already have an account?
Sign in for the live
implied-volatility monitor and alerts.
Why implied volatility matters in biotech
A clinical trial is one of the few events in finance
that is genuinely binary. The drug works or it doesn't, and the answer
arrives on a single day. Biotech companies can lose most of their value, or
multiply it, between one close and the next open — so the useful question
is not only when a readout lands, but how large a move the market
is braced for .
What it is
Implied volatility is the size of move that options traders are
collectively paying to protect against. It is a forward-looking
consensus, priced in real money, about how far a stock is likely to
travel.
Why biotech is different
A large pharmaceutical company might sit near 30% implied volatility
for years. A small biotech heading into a pivotal readout can run past
100%, sometimes far beyond — because the market knows one result is
about to reprice the entire company.
What it's good for
It ranks the calendar. Dozens of trials complete every month, and
volatility shows which ones traders think actually matter — often
building before anything is announced publicly.
What it cannot tell you: direction. High
volatility says a big move is expected, never which way. A trial that
disappoints can erase most of a company's value just as quickly as a
success can multiply it — that symmetry is precisely what the number is
measuring. Treat it as a measure of how much is at stake, not as a
prediction, and never as investment advice.
📅 Readout calendar
🧪 Recently completed
📄 Recent SEC 8-K filings
All readouts
Next 90 days
Phase 3 only
High implied volatility
Sort by IV
December 2026
Phase 3 ABP 234 Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
December 2026 Ongoing
AXSM Axsome Therapeutics Inc. Phase 3 Solriamfetol 150 mg Excessive Sleepiness; Shift-work Disorder
December 2026 Recruiting
AXSM Axsome Therapeutics Inc. Phase 3 Solriamfetol 150 mg Binge-Eating Disorder
December 2026 Recruiting
Phase 2 BHV-7000 Focal Epilepsy
December 2026 Enrolling
Phase 2/3 BHV-7000 Focal Epilepsy
December 2026 Ongoing
Phase 3 Felzartamab Antibody-mediated Rejection
December 2026 Ongoing
DNLI Denali Therapeutics Inc. Phase 1/2 DNL593 Frontotemporal Dementia
December 2026 Ongoing
DNTH Dianthus Therapeutics Inc. Phase 2 Claseprubart Multifocal Motor Neuropathy
December 2026 Ongoing
Phase 3 XL092 Non-Clear Cell Renal Cell Carcinoma
December 2026 Ongoing
Phase 3 Sacituzumab Govitecan-hziy Metastatic Breast Cancer
December 2026 Ongoing
Phase 3 Povorcitinib Hidradenitis Suppurativa (HS)
December 2026 Ongoing
Phase 2/3 Treprostinil Palmitil Pulmonary Arterial Hypertension
December 2026 Ongoing
IONS Ionis Pharmaceuticals Inc. Phase 3 Donidalorsen Hereditary Angioedema
December 2026 Ongoing
JAZZ Jazz Pharmaceuticals plc Phase 2 Zanidatamab Breast Cancer; Gastric Cancer
December 2026 Recruiting
Phase 3 KB803 Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa
December 2026 Recruiting
Phase 1/2 KB801 Neurotrophic Keratitis
December 2026 Recruiting
MANE Veradermics Incorporated Phase 3 VDPHL01 Androgenetic Alopecia; AGA
December 2026 Ongoing
MDGL Madrigal Pharmaceuticals Inc. Phase 3 Resmetirom NASH; Cirrhosis, Liver
December 2026 Ongoing
PRAX Praxis Precision Medicines Inc. Phase 3 1mg elsunersen Epileptic Encephalopathy; SCN2A Encephalopathy
December 2026 Recruiting
PRAX Praxis Precision Medicines Inc. Phase 3 1.0mg/kg/day PRAX-562 Developmental and Epileptic Encephalopathy 1
December 2026 Ongoing
REGN Regeneron Pharmaceuticals Inc. Phase 2 REGN7999 Non-Transfusion Dependent Beta-Thalassemia (NTDT)
December 2026 Ongoing
REGN Regeneron Pharmaceuticals Inc. Phase 2 Alirocumab Hypercholesterolemia
December 2026 Ongoing
SLS SELLAS Life Sciences Group Inc. Phase 1/2 SLS009 Hematologic Malignancies
December 2026 Recruiting
SUPN Supernus Pharmaceuticals Inc. Phase 1/2 BIS-001ER Focal Impaired Awareness Seizures
December 2026 Ongoing
SUPN Supernus Pharmaceuticals Inc. Phase 2 SPN-821 2400 mg Major Depressive Disorder (MDD)
December 2026 Recruiting
TARS Tarsus Pharmaceuticals Inc. Phase 2 lotilaner Ocular Rosacea
December 2026 Enrolling
UTHR United Therapeutics Corporation Phase 3 Ralinepag PAH; Pulmonary Hypertension
December 2026 Enrolling
January 2027
Phase 1/2 AMG 732 Thyroid Eye Disease
January 2027 Ongoing
Phase 3 Maridebart Cafraglutide Obesity
January 2027 Ongoing
Phase 3 Maridebart cafraglutide Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
January 2027 Ongoing
EWTX Edgewise Therapeutics Inc. Phase 2 Sevasemten Dose 1 Duchenne Muscular Dystrophy
January 2027 Ongoing
Phase 2 Tilpisertib Fosmecarbil Ulcerative Colitis
January 2027 Ongoing
IDYA IDEAYA Biosciences Inc. Phase 2/3 IDE196 Metastatic Uveal Melanoma
January 2027 Ongoing
IDYA IDEAYA Biosciences Inc. Phase 1/2 IDE196 Metastatic Uveal Melanoma; Cutaneous Melanoma
January 2027 Recruiting
Phase 1/2 INCA034176 Chronic Graft-versus-host-disease
January 2027 Ongoing
MIRM Mirum Pharmaceuticals Inc. Phase 2 Volixibat Primary Biliary Cholangitis; PBC
January 2027 Ongoing
Phase 3 mRNA-1018-H5 Influenza
January 2027 Ongoing
PRAX Praxis Precision Medicines Inc. Phase 3 40 mg/day vormatrogine for 12 weeks Focal Epilepsy
January 2027 Ongoing
RARE Ultragenyx Pharmaceutical Inc. Phase 3 setrusumab Osteogenesis Imperfecta
January 2027 Ongoing
REGN Regeneron Pharmaceuticals Inc. January 2027 Ongoing
Phase 3 Ublituximab Relapsing Multiple Sclerosis
January 2027 Recruiting
TLX Telix Pharmaceuticals Limited Phase 3 68Ga-PSMA-11 PCA; Prostate Cancer
January 2027 Ongoing
VRTX Vertex Pharmaceuticals Inc. Phase 3 Suzetrigine Diabetic Peripheral Neuropathic Pain
January 2027 Ongoing
XENE Xenon Pharmaceuticals Inc. Phase 3 Azetukalner Major Depressive Disorder
January 2027 Ongoing
February 2027
Phase 3 Sacituzumab Govitecan-hziy Triple Negative Breast Cancer; PD-L1 Positive
February 2027 Ongoing
Phase 3 KSI-101 Macular Edema Secondary to Inflammation
February 2027 Recruiting
Phase 1/2 KB707 Lung Cancer, Non-small Cell; Lung Cancer Metastatic
February 2027 Recruiting
Phase 2 LIQ861 (treprostinil) inhalation powder Raynaud's Phenomenon Secondary to Systemic Sclerosis
February 2027 Not Yet Recruiting
Phase 3 mRNA-1403 Acute Gastroenteritis; Norovirus Acute Gastroenteritis
February 2027 Ongoing
NBIX Neurocrine Biosciences Inc. Phase 2 NBI-1065890 Tardive Dyskinesia
February 2027 Recruiting
REGN Regeneron Pharmaceuticals Inc. Phase 2 REGN7508 Atrial Fibrillation (AF)
February 2027 Recruiting
REGN Regeneron Pharmaceuticals Inc. Phase 3 REGN7508 Venous Thromboembolism (VTE)
February 2027 Recruiting
VRTX Vertex Pharmaceuticals Inc. Phase 1/2 VX-670 Myotonic Dystrophy Type 1 (DM1)
February 2027 Ongoing
March 2027
Phase 2/3 Efgartigimod IV Generalized Myasthenia Gravis
March 2027 Ongoing
Phase 2 Efgartigimod PH20 SC Systemic Sclerosis (SSc)
March 2027 Ongoing
Phase 2 Cretostimogene Grenadenorepvec High-Risk Non-Muscle-Invasive Bladder Cancer
March 2027 Recruiting
DNLI Denali Therapeutics Inc. Phase 2 BIIB122 225 mg Parkinson Disease
March 2027 Ongoing
EWTX Edgewise Therapeutics Inc. Phase 2 Sevasemten Dose 1 Duchenne Muscular Dystrophy
March 2027 Ongoing
Phase 2 Oral Lenacapavir HIV-1-infection
March 2027 Recruiting
Phase 2 Sacituzumab Govitecan-hziy (SG) Non-small Cell Lung Cancer
March 2027 Ongoing
Phase 2 Domvanalimab Head and Neck Squamous Cell Carcinoma
March 2027 Ongoing
Phase 2 Anktiva Long COVID; Long COVID Syndrome
March 2027 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 3 Olezarsen Severe Hypertriglyceridemia
March 2027 Ongoing
KYKOF Kyowa Kirin Co. Ltd. Phase 2 ziftomenib Acute Myeloid Leukemia (AML)
March 2027 Recruiting
MDGL Madrigal Pharmaceuticals Inc. Phase 3 Resmetirom Non-Alcoholic Fatty Liver Disease
March 2027 Ongoing
Phase 2 mRNA-1647 Cytomegalovirus Infection
March 2027 Ongoing
RYTM Rhythm Pharmaceuticals Inc. Phase 3 Setmelanotide Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form
March 2027 Recruiting
TVTX Travere Therapeutics Inc. Phase 2 Sparsentan Focal Segmental Glomerulosclerosis; Minimal Change Disease
March 2027 Recruiting
VRTX Vertex Pharmaceuticals Inc. Phase 1/2 VX-264 Type 1 Diabetes
March 2027 Ongoing
VRTX Vertex Pharmaceuticals Inc. Phase 2 VX-993 Diabetic Peripheral Neuropathic Pain
March 2027 Recruiting
Phase 3 ZL-1109 (VRDN-003) Thyroid Eye Disease (TED)
March 2027 Ongoing
April 2027
ALNY Alnylam Pharmaceuticals Inc. April 2027 Recruiting
Phase 2 Inebilizumab Neuromyelitis Optica Spectrum Disorder
April 2027 Recruiting
Phase 3 Ocrelizumab (US) Relapsing-remitting Multiple Sclerosis (RRMS)
April 2027 Ongoing
Phase 3 Maridebart cafraglutide Obesity Disease
April 2027 Ongoing
Phase 2 Efgartigimod PH20 SC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
April 2027 Ongoing
BMRN BioMarin Pharmaceutical Inc. Phase 1/2 BMN 351 Duchenne Muscular Dystrophy
April 2027 Ongoing
Phase 3 BNT162b2 COVID-19 Vaccines
April 2027 Recruiting
Phase 2 GLK-221 Ophthalmic Solution Keratoconus
April 2027 Recruiting
HRMY Harmony Biosciences Holdings Inc. Phase 3 Pitolisant tablet Prader-Willi Syndrome
April 2027 Recruiting
IDYA IDEAYA Biosciences Inc. Phase 2 Darovasertib Uveal Melanoma
April 2027 Ongoing
Phase 2 INCB123667 Ovarian Cancer
April 2027 Recruiting
Phase 3 Ruxolitinib Cream NonSegmental Vitiligo
April 2027 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 1/2 ION717 Prion Disease
April 2027 Ongoing
Phase 3 KSI-101 Macular Edema Secondary to Inflammation
April 2027 Recruiting
KYKOF Kyowa Kirin Co. Ltd. Phase 1/2 KK2430 Hematologic Neoplasms
April 2027 Recruiting
LGND Ligand Pharmaceuticals Incorporated Phase 3 Lasofoxifene + abemaciclib ER+/HER2- breast cancer with an ESR1 mutation
April 2027 Enrollment Initiation
VRTX Vertex Pharmaceuticals Inc. Phase 3 ELX/TEZ/IVA Cystic Fibrosis
April 2027 Ongoing
VRTX Vertex Pharmaceuticals Inc. Phase 3 Suzetrigine Diabetic Peripheral Neuropathic Pain
April 2027 Recruiting
XENE Xenon Pharmaceuticals Inc. Phase 3 XEN1101 Primary Generalized Tonic-Clonic Seizures
April 2027 Recruiting
May 2027
ALNY Alnylam Pharmaceuticals Inc. Phase 2 ALN-4324 Type 2 Diabetes Mellitus (T2DM)
May 2027 Ongoing
Phase 3 BIIB017 (peginterferon beta-1a) Multiple Sclerosis, Relapsing-Remitting
May 2027 Ongoing
Phase 3 Felzartamab Immunoglobulin A Nephropathy (IgAN)
May 2027 Recruiting
CRNX Crinetics Pharmaceuticals Inc. Phase 3 Atumelnant Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
May 2027 Recruiting
Phase 1/2 Sacituzumab Govitecan-hziy Advanced Solid Tumor; Metastatic Triple-Negative Breast Cancer
May 2027 Ongoing
Phase 2 Gemcitabine Platinum-resistant Ovarian Cancer
May 2027 Recruiting
Phase 2 CD19 t-haNK- IV Administration Relapsed B-Cell Non Hodgkin Lymphoma
May 2027 Recruiting
Phase 2 IMVT-1402 Graves' Disease
May 2027 Recruiting
Phase 1/2 DISC-0974 Myelofibrosis; Anemia; Anemia
May 2027 Recruiting
KLRA Kailera Therapeutics Inc. May 2027 Ongoing
RYTM Rhythm Pharmaceuticals Inc. Phase 1/2 Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) Hypothalamic Obesity; Prader-Willi Syndrome
May 2027 Ongoing
VRTX Vertex Pharmaceuticals Inc. Phase 3 Suzetrigine Diabetic Peripheral Neuropathic Pain
May 2027 Recruiting
XENE Xenon Pharmaceuticals Inc. Phase 3 Azetukalner Major Depressive Disorder
May 2027 Ongoing
June 2027
ALNY Alnylam Pharmaceuticals Inc. Phase 2 ALN-6400 Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB)
June 2027 Recruiting
Phase 3 Tinlarebant Geographic Atrophy
June 2027 Ongoing
Phase 2 BNT327 Dose Level 1 (DL1) Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer
June 2027 Ongoing
Phase 2 BNT166a Mpox (Monkeypox); Smallpox
June 2027 Recruiting
DNLI Denali Therapeutics Inc. Phase 2/3 tividenofusp alfa Mucopolysaccharidosis II
June 2027 Enrolling
Phase 3 Sacituzumab govitecan-hziy (SG) Triple Negative Breast Cancer
June 2027 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 3 Olezarsen Familial Chylomicronemia Syndrome
June 2027 Ongoing
KYMR Kymera Therapeutics Inc. Phase 2 KT-621 Atopic Dermatitis
June 2027 Ongoing
MANE Veradermics Incorporated Phase 3 VDPHL01 QD Androgenetic Alopecia (AGA); Androgenetic Alopecia
June 2027 Ongoing
MIRM Mirum Pharmaceuticals Inc. Phase 3 Brelovitug 300 mg Chronic Hepatitis D Infection
June 2027 Recruiting
Phase 3 Deucrictibant Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
June 2027 Recruiting
Phase 2/3 deucrictibant Hereditary Angioedema; Hereditary Angioedema Type I
June 2027 Enrolling
SYRE Spyre Therapeutics Inc. Phase 2 SPY001 Ulcerative Colitis; Inflammatory Bowel Diseases
June 2027 Recruiting
VRTX Vertex Pharmaceuticals Inc. Phase 3 CTX001 Sickle Cell Disease; Hydroxyurea Failure
June 2027 Ongoing
July 2027
Phase 3 Efgartigimod PH20 SC Primary Sjogrens Disease
July 2027 Ongoing
COAG Hemab Therapeutics Holdings Inc. Phase 1/2 HMB-002 (Part A) Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1
July 2027 Recruiting
Phase 2 INCB000928 Fibrodysplasia Ossificans Progressiva (FOP)
July 2027 Recruiting
Phase 2 DISC-3405 Polycythemia Vera (PV)
July 2027 Ongoing
KLRA Kailera Therapeutics Inc. Phase 2 KAI-7535 Obesity; Overweight
July 2027 Ongoing
Phase 1/2 KB707 Cancer; Melanoma Stage III
July 2027 Recruiting
NBIX Neurocrine Biosciences Inc. Phase 3 NBI-1065845 Major Depressive Disorder
July 2027 Recruiting
NBIX Neurocrine Biosciences Inc. Phase 3 NBI-1065845 Major Depressive Disorder
July 2027 Recruiting
NBIX Neurocrine Biosciences Inc. Phase 3 NBI-1065845 Major Depressive Disorder
July 2027 Recruiting
Phase 2 Ublituximab Multiple Sclerosis
July 2027 Recruiting
TVTX Travere Therapeutics Inc. Phase 1/2 Pegtibatinase Homocystinuria
July 2027 Recruiting
VKTX Viking Therapeutics Inc. July 2027 Ongoing
VKTX Viking Therapeutics Inc. July 2027 Ongoing
August 2027
ACAD ACADIA Pharmaceuticals Inc. Phase 2 ACP-211 Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant
August 2027 Recruiting
ALNY Alnylam Pharmaceuticals Inc. Phase 2 ALN-APP Cerebral Amyloid Angiopathy
August 2027 Ongoing
ALNY Alnylam Pharmaceuticals Inc. Phase 1/2 ALN-4324 Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)
August 2027 Ongoing
Phase 2/3 BHV-8000 10mg Parkinson Disease
August 2027 Recruiting
Phase 3 Tofersen Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
August 2027 Ongoing
COAG Hemab Therapeutics Holdings Inc. Phase 1/2 HMB-001 Glanzmann Thrombasthenia
August 2027 Ongoing
CRNX Crinetics Pharmaceuticals Inc. Phase 3 Paltusotine Carcinoid Syndrome; Carcinoid
August 2027 Ongoing
CRNX Crinetics Pharmaceuticals Inc. Phase 1/2 CRN09682 SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors
August 2027 Ongoing
Phase 2 Nogapendekin alfa inbakicept (NAI) Sepsis; Septic Shock
August 2027 Not Yet Recruiting
Phase 2 Tafasitamab Hematologic Malignancies
August 2027 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 3 obudanersen Angelman Syndrome
August 2027 Ongoing
LNTH Lantheus Holdings Inc. Phase 1/2 LNTH2403 Phase 1 dose Relapsed / Refractory Osteosarcoma
August 2027 Recruiting
MIRM Mirum Pharmaceuticals Inc. Phase 2/3 Brelovitug (BJT-778) Chronic Hepatitis D
August 2027 Recruiting
Phase 1/2 mRNA-3927 Propionic Acidemia
August 2027 Recruiting
NBIX Neurocrine Biosciences Inc. Phase 2 NBI-1117570 Schizophrenia
August 2027 Recruiting
RARE Ultragenyx Pharmaceutical Inc. Phase 3 No Investigational Product Mucopolysaccharidosis IIIA; MPS IIIA
August 2027 Enrolling
RARE Ultragenyx Pharmaceutical Inc. Phase 3 Triheptanoin Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
August 2027 Ongoing
SUPN Supernus Pharmaceuticals Inc. Phase 2 SPN-817 Focal Onset Seizures
August 2027 Recruiting
TLX Telix Pharmaceuticals Limited Phase 3 177Lu-TLX250 ccRCC; Renal Cell Carcinoma (Kidney Cancer)
August 2027 Recruiting
TRVI Trevi Therapeutics Inc. Phase 3 NAL ER Idiopathic Pulmonary Fibrosis
August 2027 Recruiting
TVTX Travere Therapeutics Inc. Phase 3 Pegtibatinase Homocystinuria
August 2027 Recruiting
Phase 1/2 ZL-1310 Solid Tumors
August 2027 Recruiting
September 2027
Phase 2/3 Efgartigimod PH20 SC Generalized Myasthenia Gravis
September 2027 Recruiting
Phase 3 empasiprubart Chronic Inflammatory Demyelinating Polyneuropathy; CIDP
September 2027 Recruiting
Phase 3 Nusinersen Spinal Muscular Atrophy
September 2027 Ongoing
DFTX Definium Therapeutics Inc. Phase 3 DT120 Major Depressive Disorder
September 2027 Recruiting
Phase 3 Alpha-1 15% Alpha 1 Antitrypsin Deficiency
September 2027 Recruiting
Phase 2 IMVT-1402 Rheumatoid Arthritis
September 2027 Ongoing
IONS Ionis Pharmaceuticals Inc. Phase 2 ION775 Hypertriglyceridemia; Severe Hypertriglyceridemia
September 2027 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 1/2 ION440 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
September 2027 Recruiting
PTCT PTC Therapeutics Inc. Phase 2 PTC844 Rheumatoid Arthritis
September 2027 Recruiting
RARE Ultragenyx Pharmaceutical Inc. Phase 3 DTX301 OTC Deficiency
September 2027 Ongoing
TRVI Trevi Therapeutics Inc. Phase 2 NAL ER Refractory Chronic Cough
September 2027 Recruiting
October 2027
Phase 2 Empasiprubart IV AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG)
October 2027 Recruiting
HRMY Harmony Biosciences Holdings Inc. Phase 3 HBS-301 tablet Idiopathic Hypersomnia
October 2027 Recruiting
HRMY Harmony Biosciences Holdings Inc. Phase 3 HBS-301 EDS; Cataplexy
October 2027 Recruiting
MIRM Mirum Pharmaceuticals Inc. Phase 2 Low dose of MRM-3379 Fragile X Syndrome
October 2027 Recruiting
NBIX Neurocrine Biosciences Inc. Phase 3 NBI-1117568 Schizophrenia
October 2027 Recruiting
ORKA Oruka Therapeutics Inc. Phase 2 ORKA-002 Plaque Psoriasis
October 2027 Ongoing
SYRE Spyre Therapeutics Inc. Phase 2 SPY072 Hidradenitis Suppurativa (HS)
October 2027 Recruiting
TARS Tarsus Pharmaceuticals Inc. Phase 2 TP-05 (lotilaner) Low Dose Lyme Disease
October 2027 Ongoing
November 2027
Phase 3 Omaveloxolone Friedreich Ataxia
November 2027 Ongoing
Phase 1/2 BNT3212 Advanced Solid Tumor
November 2027 Recruiting
COAG Hemab Therapeutics Holdings Inc. Phase 2 Sutacimig Congenital Factor VII Deficiency
November 2027 Recruiting
NAMS NewAmsterdam Pharma Company N.V. Phase 3 obicetrapib 10 mg + ezetimibe 10 mg FDC daily Lipidemia; Coronary Artery Disease
November 2027 Ongoing
NBIX Neurocrine Biosciences Inc. Phase 3 NBI-1117568 Schizophrenia
November 2027 Recruiting
UTHR United Therapeutics Corporation Phase 3 Inhaled Treprostinil Progressive Pulmonary Fibrosis; Interstitial Lung Disease
November 2027 Recruiting
VERA Vera Therapeutics Inc. Phase 2 Atacicept pMN; IgAN
November 2027 Recruiting
December 2027
Phase 2 envudeucitinib Plaque Psoriasis
December 2027 Ongoing
ALNY Alnylam Pharmaceuticals Inc. Phase 3 Nucresiran Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
December 2027 Recruiting
AXSM Axsome Therapeutics Inc. Phase 3 AXS-05 (dextromethorphan-bupropion) Smoking Cessation
December 2027 Recruiting
AXSM Axsome Therapeutics Inc. Phase 3 Solriamfetol Binge-Eating Disorder
December 2027 Enrolling
AXSM Axsome Therapeutics Inc. December 2027 Enrolling
BMRN BioMarin Pharmaceutical Inc. Phase 1/2 BMN 307 Phenylketonuria (PKU)
December 2027 Ongoing
BMRN BioMarin Pharmaceutical Inc. Phase 2 BMN 111 Achondroplasia
December 2027 Ongoing
BMRN BioMarin Pharmaceutical Inc. Phase 2 vosoritide Achondroplasia
December 2027 Ongoing
Phase 2 Pumitamig Pancreatic Ductal Adenocarcinoma (PDAC)
December 2027 Recruiting
DNLI Denali Therapeutics Inc. Phase 2/3 tividenofusp alfa Mucopolysaccharidosis II
December 2027 Ongoing
EWTX Edgewise Therapeutics Inc. Phase 2 EDG-15400 25 mg Heart Failure With Preserved Ejection Fraction
December 2027 Recruiting
EWTX Edgewise Therapeutics Inc. Phase 2 EDG-7500 Hypertrophic Cardiomyopathy
December 2027 Ongoing
Phase 3 Gamunex-C CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
December 2027 Recruiting
Phase 2 CD19 t-haNK- IV Administration Relapsed B-Cell Non-Hodgkin Lymphoma
December 2027 Not Yet Recruiting
Phase 3 IMVT-1402 Generalized Myasthenia Gravis
December 2027 Recruiting
JAZZ Jazz Pharmaceuticals plc Phase 3 Xywav Narcolepsy; Idiopathic Hypersomnia
December 2027 Recruiting
JAZZ Jazz Pharmaceuticals plc Phase 2 Zanidatamab HER2-positive Breast Cancer; Breast Cancer
December 2027 Recruiting
KNSA Kiniksa Pharmaceuticals International plc Phase 2/3 KPL-387 Pericarditis; Pericarditis Acute
December 2027 Recruiting
KNSA Kiniksa Pharmaceuticals International plc Phase 2 KPL-387 Recurrent Pericarditis; Heart Diseases
December 2027 Recruiting
KYMR Kymera Therapeutics Inc. Phase 2 KT-621 Eosinophilic Asthma
December 2027 Recruiting
Phase 2 0.5 mL of the low dose VAX-31 Pneumococcal Vaccines
December 2027 Ongoing
PTCT PTC Therapeutics Inc. Phase 3 Vatiquinone Friedreich Ataxia
December 2027 Ongoing
SUPN Supernus Pharmaceuticals Inc. Phase 2 SPN-817 Epilepsy; Seizures, Epileptic
December 2027 Recruiting
SUPN Supernus Pharmaceuticals Inc. Phase 2 SPN-817 Focal Onset Seizures
December 2027 Enrolling
TLX Telix Pharmaceuticals Limited Phase 3 177Lu-TLX591 Metastatic Castration-resistant Prostate Cancer
December 2027 Recruiting
January 2028
ACAD ACADIA Pharmaceuticals Inc. Phase 2/3 ACP-204 Alzheimer's Disease Psychosis
January 2028 Recruiting
ALNY Alnylam Pharmaceuticals Inc. Phase 1/2 ALN-6400 Hereditary Hemorrhagic Telangiectasia
January 2028 Ongoing
Phase 3 BHV-1300 Graves Disease
January 2028 Recruiting
Phase 2 Felzartamab Graves' Disease
January 2028 Recruiting
Phase 2 Pumitamig Recurrent Glioblastoma
January 2028 Recruiting
Phase 1/2 Gedatolisib mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male
January 2028 Recruiting
JAZZ Jazz Pharmaceuticals plc Phase 1/2 Lurbinectedin Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma
January 2028 Recruiting
Phase 3 Canvuparatide Hypoparathyroidism
January 2028 Recruiting
MDGL Madrigal Pharmaceuticals Inc. Phase 3 MGL-3196 NASH - Nonalcoholic Steatohepatitis
January 2028 Ongoing
NRIX Nurix Therapeutics Inc. Phase 2 NX-5948 Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
January 2028 Recruiting
XENE Xenon Pharmaceuticals Inc. Phase 3 XEN1101 Focal Onset Seizures
January 2028 Recruiting
February 2028
ACAD ACADIA Pharmaceuticals Inc. Phase 2 ACP-204 Lewy Body Dementia Psychosis
February 2028 Recruiting
Phase 1/2 BHV-1510 Solid Tumor
February 2028 Recruiting
Phase 2 Felzartamab Microvascular Inflammation
February 2028 Recruiting
Phase 2/3 Tinlarebant STGD1; Stargardt Disease 1
February 2028 Ongoing
Phase 2 Zanzalintinib Meningioma
February 2028 Recruiting
Phase 1/2 Intravesical Recombinant Mycobacterium (rMBCG) NMIBC
February 2028 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 3 Olezarsen Familial Chylomicronemia Syndrome
February 2028 Ongoing
KLRA Kailera Therapeutics Inc. Phase 3 Ribupatide Obesity; Overweight
February 2028 Ongoing
NBIX Neurocrine Biosciences Inc. Phase 2 NBI-1117568 Bipolar I Disorder; Mania
February 2028 Recruiting
March 2028
ALNY Alnylam Pharmaceuticals Inc. Phase 3 Vutrisiran Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
March 2028 Enrolling
AXSM Axsome Therapeutics Inc. Phase 3 AXS-14 (Esreboxetine) Fibromyalgia
March 2028 Recruiting
Phase 1/2 BNT326 Advanced Solid Tumor
March 2028 Recruiting
Phase 2 Gen 2 Travoprost Intracameral Implant Glaucoma
March 2028 Recruiting
HALO Halozyme Therapeutics Inc. Phase 3 Testosterone enanthate Hypogonadism, Male
March 2028 Recruiting
KLRA Kailera Therapeutics Inc. March 2028 Ongoing
KLRA Kailera Therapeutics Inc. Phase 3 Ribupatide Obesity With Diabetes; Overweight With Diabetes
March 2028 Ongoing
LNTH Lantheus Holdings Inc. Phase 3 [18F]PI-2620 Alzheimer Disease
March 2028 Recruiting
NAMS NewAmsterdam Pharma Company N.V. Phase 3 obicetrapib 10 mg + ezetimibe 10 mg FDC daily Lipidemia; Type 2 Diabetes (T2DM)
March 2028 Ongoing
April 2028
ARQT Arcutis Biotherapeutics Inc. Phase 3 Roflumilast Cream 0.3% Atopic Dermatitis; Atopic Dermatitis (AD)
April 2028 Recruiting
Phase 3 Naporafenib Advanced or Metastatic NRAS-mutant Melanoma
April 2028 Ongoing
JAZZ Jazz Pharmaceuticals plc Phase 3 Zanidatamab Metastatic HER2-positive Breast Cancer
April 2028 Recruiting
RCUS Arcus Biosciences Inc. Phase 3 Casdatifan Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma
April 2028 Recruiting
RLAY Relay Therapeutics Inc. Phase 3 Zovegalisib PIK3CA Mutation; HER2- Negative Breast Cancer
April 2028 Recruiting
RYTM Rhythm Pharmaceuticals Inc. Phase 2 Bivamelagon Hypothalamic Obesity
April 2028 Enrolling
TLX Telix Pharmaceuticals Limited Phase 3 Floretyrosine F 18 ([18F]FET) Brain Metastasis; Radiation Necrosis
April 2028 Not Yet Recruiting
May 2028
AXSM Axsome Therapeutics Inc. Phase 3 AXS-14 (esreboxetine) Fibromyalgia
May 2028 Enrolling
Phase 2 Nogapendekin alfa inbakicept (NAI) Sepsis
May 2028 Not Yet Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 3 obudanersen Angelman Syndrome
May 2028 Recruiting
KYKOF Kyowa Kirin Co. Ltd. Phase 2 ME-401 Indolent B-cell Non-Hodgkin's Lymphoma
May 2028 Ongoing
Phase 2 400 µg of MBX 2109 once-weekly by subcutaneous injection Hypoparathyroidism
May 2028 Ongoing
Phase 3 Rezpegaldesleukin Moderate-to-Severe Atopic Dermatitis
May 2028 Recruiting
PRAX Praxis Precision Medicines Inc. Phase 3 vormatrogine Epilepsy, Tonic-Clonic; Focal Seizure
May 2028 Enrolling
UTHR United Therapeutics Corporation Phase 2 treprostinil SMI (treprostinil inhalation spray) Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
May 2028 Not Yet Recruiting
June 2028
AXSM Axsome Therapeutics Inc. Phase 3 Solriamfetol Dose A ADHD
June 2028 Recruiting
BMRN BioMarin Pharmaceutical Inc. Phase 2 Vosoritide Hypochondroplasia
June 2028 Recruiting
CLDX Celldex Therapeutics Inc. Phase 3 Barzolvolimab Chronic Inducible Urticaria; Cold Urticaria
June 2028 Recruiting
Phase 2 Carboplatin Squamous Non-Small Cell Lung Cancer (NSCLC)
June 2028 Recruiting
Phase 3 Gen 2 Travoprost Intracameral Implant Glaucoma
June 2028 Recruiting
Phase 2 IMVT-1402 Graves' Disease
June 2028 Recruiting
Phase 2/3 DISC-1459 Erythropoietic Protoporphyria
June 2028 Enrolling
JAZZ Jazz Pharmaceuticals plc Phase 3 Dordaviprone (ONC201) H3 K27M; Glioma
June 2028 Recruiting
Phase 3 Rezpegaldesleukin Moderate-to-Severe Atopic Dermatitis
June 2028 Recruiting
TRVI Trevi Therapeutics Inc. Phase 3 NAL ER Idiopathic Pulmonary Fibrosis
June 2028 Recruiting
XENE Xenon Pharmaceuticals Inc. Phase 3 Azetukalner Bipolar Disorder; Bipolar Depression
June 2028 Ongoing
Phase 3 ZL-1310 Small-cell Lung Cancer
June 2028 Recruiting
July 2028
CRSP CRISPR Therapeutics AG Phase 1/2 CTX340 Hypertension
July 2028 Recruiting
DYN Dyne Therapeutics Inc. Phase 3 zeleciment basivarsen (DYNE-101) Myotonic Dystrophy Type 1 (DM1); DM1
July 2028 Recruiting
Phase 2 IMVT-1402 Primary Sjögren's Syndrome
July 2028 Ongoing
TARS Tarsus Pharmaceuticals Inc. Phase 2 TP-06 Persistent Corneal Epithelial Defect
July 2028 Recruiting
Phase 2 Ublituximab Myasthenia Gravis
July 2028 Recruiting
TLX Telix Pharmaceuticals Limited Phase 3 TLX-101-Tx + Lomustine Neoplastic Disease; Glioblastoma
July 2028 Recruiting
VKTX Viking Therapeutics Inc. July 2028 Recruiting
August 2028
Phase 2/3 Zanzalintinib Head and Neck Squamous Cell Carcinoma
August 2028 Ongoing
Phase 3 Gamunex-C, 10% Injectable Solution Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
August 2028 Recruiting
Phase 2 Imeroprubart Chronic Inflammatory Demyelinating Polyneuropathy
August 2028 Recruiting
JAZZ Jazz Pharmaceuticals plc Phase 2/3 JZP926 capsule Juvenile Myoclonic Epilepsy
August 2028 Recruiting
Phase 3 Tabirafusp tedromer Diabetic Macular Edema (DME)
August 2028 Recruiting
MDGL Madrigal Pharmaceuticals Inc. Phase 2 Resmetirom MASH - Metabolic Dysfunction-Associated Steatohepatitis
August 2028 Recruiting
September 2028
Phase 3 BHV-1400 IgA Nephropathy
September 2028 Not Yet Recruiting
CLDX Celldex Therapeutics Inc. Phase 3 barzolvolimab Chronic Spontaneous Urticaria
September 2028 Enrolling
Phase 3 Alpha-1 MP Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
September 2028 Enrolling
Phase 3 N-803 NSCLC Stage IV
September 2028 Recruiting
NAMS NewAmsterdam Pharma Company N.V. Phase 2 Obicetrapib 10 mg Preclinical Alzheimer's Disease
September 2028 Recruiting
October 2028
JAZZ Jazz Pharmaceuticals plc October 2028 Recruiting
Phase 3 NovoTTF-200T Metastatic Non-small Cell Lung Cancer
October 2028 Recruiting
ORKA Oruka Therapeutics Inc. Phase 2 ORKA-002 Hidradenitis Suppurativa (HS)
October 2028 Recruiting
UTHR United Therapeutics Corporation Phase 1/2 10 GE Xenokidney ESRD (End-Stage Renal Disease); Kidney Transplantation
October 2028 Recruiting
VKTX Viking Therapeutics Inc. Phase 3 VK2735 Oral Weight Loss
October 2028 Recruiting
November 2028
Phase 3 Open-Label Envudeucitinib Plaque Psoriasis; Psoriasis (PsO)
November 2028 Ongoing
BMRN BioMarin Pharmaceutical Inc. Phase 1/2 Dose 1 of BMN 331 Hereditary Angioedema; HAE
November 2028 Ongoing
Phase 2 mRNA-1982 Lyme Disease
November 2028 Ongoing
December 2028
Phase 2/3 BHV-1300 Graves' Disease
December 2028 Not Yet Recruiting
DNTH Dianthus Therapeutics Inc. Phase 3 Claseprubart Myasthenia Gravis, Generalized
December 2028 Recruiting
DNTH Dianthus Therapeutics Inc. Phase 3 Claseprubart Chronic Inflammatory Demyelinating Polyneuropathy
December 2028 Recruiting
ELVN Enliven Therapeutics Inc. Phase 3 ELVN-001 Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Pos
December 2028 Not Yet Recruiting
Phase 3 Treprostinil Palmitil Inhalation Powder Pulmonary Arterial Hypertension
December 2028 Recruiting
Phase 3 Treprostinil Palmitil Inhalation Powder Pulmonary Hypertension; Interstitial Lung Disease
December 2028 Recruiting
KYMR Kymera Therapeutics Inc. Phase 2 KT-621 Asthma (Diagnosis)
December 2028 Recruiting
Phase 3 Deucrictibant Hereditary Angioedema (HAE)
December 2028 Enrolling
RARE Ultragenyx Pharmaceutical Inc. Phase 1/2 UX016 GNE Myopathy
December 2028 Recruiting
Phase 2 Ublituximab Schizophrenia
December 2028 Recruiting
TLX Telix Pharmaceuticals Limited Phase 2 177Lu-TLX250 ccRCC; Renal Cell Carcinoma (Kidney Cancer)
December 2028 Not Yet Recruiting
January 2029
MIRM Mirum Pharmaceuticals Inc. Phase 2 Maralixibat Intrahepatic Cholestasis of Pregnancy
January 2029 Not Yet Recruiting
Phase 2 mRNA-1195 Multiple Sclerosis
January 2029 Recruiting
February 2029
ACAD ACADIA Pharmaceuticals Inc. Phase 3 ACP-204 Lewy Body Dementia Psychosis
February 2029 Recruiting
March 2029
AGIO Agios Pharmaceuticals Inc. Phase 3 Mitapivat Non-Transfusion-dependent Alpha-Thalassemia; Non-Transfusion-dependent Beta-Thalassemia
March 2029 Recruiting
Phase 3 Arm A: Gedatolisib + Palbociclib + Fulvestrant Breast Cancer
March 2029 Recruiting
IONS Ionis Pharmaceuticals Inc. Phase 1/2 ION582 Angelman Syndrome
March 2029 Ongoing
PTCT PTC Therapeutics Inc. Phase 3 Vatiquinone Friedreich's Ataxia
March 2029 Not Yet Recruiting
RARE Ultragenyx Pharmaceutical Inc. Phase 2/3 UX111 MPS IIIA; Sanfilippo Syndrome
March 2029 Recruiting
RARE Ultragenyx Pharmaceutical Inc. Phase 1/2 UX701 Wilson Disease
March 2029 Ongoing
SYRE Spyre Therapeutics Inc. Phase 2 SPY001 Ulcerative Colitis; Inflammatory Bowel Diseases
March 2029 Enrolling
April 2029
ACAD ACADIA Pharmaceuticals Inc. Phase 3 ACP-204 Alzheimer's Disease Psychosis
April 2029 Enrolling
Phase 3 Optune® device Glioblastoma
April 2029 Ongoing
May 2029
KYKOF Kyowa Kirin Co. Ltd. Phase 3 KK8398 Achondroplasia
May 2029 Ongoing
MIRM Mirum Pharmaceuticals Inc. Phase 2/3 Brelovitug 300 mg Chronic Hepatitis D Infection
May 2029 Ongoing
RLAY Relay Therapeutics Inc. Phase 1/2 RLY-8161 Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors
May 2029 Recruiting
June 2029
AGIO Agios Pharmaceuticals Inc. Phase 3 Mitapivat Matched Placebo Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia
June 2029 Recruiting
BMRN BioMarin Pharmaceutical Inc. Phase 2/3 BMN 333 Achondroplasia
June 2029 Recruiting
Phase 2/3 Zanzalintinib Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)
June 2029 Recruiting
XENE Xenon Pharmaceuticals Inc. Phase 3 Azetukalner Bipolar Depression; Bipolar I Disorder
June 2029 Ongoing
July 2029
CRNX Crinetics Pharmaceuticals Inc. Phase 2 atumelnant (CRN04894) Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
July 2029 Recruiting
DYN Dyne Therapeutics Inc. Phase 1/2 DYNE-101 Myotonic Dystrophy Type 1 (DM1)
July 2029 Ongoing
IDYA IDEAYA Biosciences Inc. Phase 1/2 IDE849 Small-cell Lung Cancer; Neuroendocrine Carcinomas
July 2029 Recruiting
Phase 3 L606 Pulmonary Hypertension Due to Lung Disease (Disorder)
July 2029 Recruiting
MDGL Madrigal Pharmaceuticals Inc. Phase 2 Resmetirom MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis
July 2029 Recruiting
ORKA Oruka Therapeutics Inc. Phase 2 ORKA-002 Plaque Psoriasis
July 2029 Enrolling
August 2029
AGIO Agios Pharmaceuticals Inc. Phase 3 Mitapivat Matched Placebo Sickle Cell Disease
August 2029 Recruiting
Phase 3 Xembify Hypogammaglobulinemia; Bacterial Infections
August 2029 Recruiting
Phase 2 N-803 + Pembrolizumab Non-Small Cell Lung Cancer; Small Cell Lung Cancer
August 2029 Ongoing
Phase 2 mRNA-1283 SARS-CoV-2
August 2029 Recruiting
September 2029
LNTH Lantheus Holdings Inc. Phase 2/3 [68Ga]-LNTH-2401 Prostate Cancer
September 2029 Recruiting
October 2029
NRIX Nurix Therapeutics Inc. Phase 3 NX-5948 B-cell Lymphoma; Chronic Lymphocytic Leukemia
October 2029 Recruiting
November 2029
COAG Hemab Therapeutics Holdings Inc. Phase 3 Sutacimig Thrombasthenia
November 2029 Recruiting
UTHR United Therapeutics Corporation Phase 1/2 GGTA1 KO Thymokidney ESRD (End-Stage Renal Disease); Kidney Transplantation
November 2029 Recruiting
December 2029
CRSP CRISPR Therapeutics AG Phase 1/2 CTX112 Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica
December 2029 Not Yet Recruiting
UTHR United Therapeutics Corporation Phase 3 Inhaled Treprostinil Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
December 2029 Enrolling
January 2030
CRSP CRISPR Therapeutics AG Phase 1/2 CTX112 B-cell Lymphoma; Non-Hodgkin Lymphoma
January 2030 Recruiting
Phase 2/3 Ublituximab Relapsing Multiple Sclerosis
January 2030 Recruiting
March 2030
CRNX Crinetics Pharmaceuticals Inc. Phase 2/3 Atumelnant Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
March 2030 Recruiting
Phase 2 IMVT-1402 Graves' Disease
March 2030 Enrolling
April 2030
Phase 3 Zanzalintinib Colorectal Cancer
April 2030 Recruiting
May 2030
Phase 3 Cabozantinib Cancer; Renal Cell Carcinoma (RCC)
May 2030 Enrolling
ORKA Oruka Therapeutics Inc. Phase 2 ORKA-001 Plaque Psoriasis
May 2030 Recruiting
June 2030
Phase 3 Cretostimogene Grenadenorepvec Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer
June 2030 Ongoing
CRSP CRISPR Therapeutics AG Phase 1/2 CTX460 Alpha-1 Antitrypsin Deficiency (AATD)
June 2030 Recruiting
KYKOF Kyowa Kirin Co. Ltd. Phase 1/2 KK8123 X-linked Hypophosphatemia
June 2030 Recruiting
Phase 3 ZL-1310 in combination with Atezolizumab or Durvalumab Extensive-Stage Small Cell Lung Cancer
June 2030 Not Yet Recruiting
August 2030
AGIO Agios Pharmaceuticals Inc. Phase 2/3 AG-236 Polycythemia Vera
August 2030 Not Yet Recruiting
HRMY Harmony Biosciences Holdings Inc. Phase 3 Pitolisant Prader-Willi Syndrome
August 2030 Enrolling
Phase 3 Treprostinil Palmitil Inhalation Powder Progressive Pulmonary Fibrosis; Interstitial Lung Disease
August 2030 Recruiting
TVTX Travere Therapeutics Inc. Phase 3 Pegtibatinase Homocystinuria
August 2030 Enrolling
October 2030
IDYA IDEAYA Biosciences Inc. Phase 3 Darovasertib Uveal Melanoma
October 2030 Recruiting
November 2030
RCUS Arcus Biosciences Inc. Phase 3 Quemliclustat Metastatic Pancreatic Ductal Adenocarcinoma
November 2030 Ongoing
December 2030
DYN Dyne Therapeutics Inc. Phase 3 Zeleciment Rostudirsen (DYNE-251) Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne
December 2030 Recruiting
January 2031
Phase 3 Treprostinil Palmitil Inhalation Powder Pulmonary Hypertension; Interstitial Lung Disease
January 2031 Recruiting
February 2031
DNLI Denali Therapeutics Inc. Phase 1/2 tividenofusp alfa Mucopolysaccharidosis II
February 2031 Ongoing
EWTX Edgewise Therapeutics Inc. Phase 2 Sevasemten Becker Muscular Dystrophy
February 2031 Enrolling
PTCT PTC Therapeutics Inc. Phase 3 Sepiapterin Phenylketonuria
February 2031 Recruiting
May 2031
VERA Vera Therapeutics Inc. Phase 2 Atacicept 150 mg IgA Nephropathy (IgAN); Renal and Urinary Disorders
May 2031 Enrolling
June 2031
BMRN BioMarin Pharmaceutical Inc. Phase 3 BMN 111 Achondroplasia
June 2031 Ongoing
July 2031
RLAY Relay Therapeutics Inc. Phase 2 RLY-2608 PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations
July 2031 Recruiting
September 2031
DYN Dyne Therapeutics Inc. Phase 1/2 DYNE-251 Duchenne Muscular Dystrophy (DMD)
September 2031 Ongoing
May 2032
Phase 3 Ublituximab Relapsing Multiple Sclerosis (RMS)
May 2032 Ongoing
July 2032
DNLI Denali Therapeutics Inc. Phase 1/2 DNL126 Mucopolysaccharidosis Type IIIA
July 2032 Recruiting
April 2033
XENE Xenon Pharmaceuticals Inc. Phase 3 XEN1101 Focal Epilepsy; Tonic-Clonic Seizures
April 2033 Enrolling
May 2033
NRIX Nurix Therapeutics Inc. Phase 1/2 NX-5948 B-cell Lymphoma; Chronic Lymphocytic Leukemia
May 2033 Recruiting
December 2033
CRSP CRISPR Therapeutics AG Phase 1/2 CTX112 Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia
December 2033 Recruiting
March 2034
IDYA IDEAYA Biosciences Inc. Phase 3 Darovasertib Uveal Melanoma
March 2034 Recruiting
September 2034
UTHR United Therapeutics Corporation Phase 2/3 treprostinil SMI (treprostinil inhalation spray) Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
September 2034 Not Yet Recruiting
Want alerts instead of checking?
The full monitor adds notifications the moment a readout date arrives or a
company files an 8-K, on your desktop and phone — plus per-company trial
timelines across 107 biotechs.
Start free for 28 days
or sign in →
Trial data from ClinicalTrials.gov (U.S. National Library of Medicine) and
filings from SEC EDGAR — both U.S. government works in the public domain.
This page is not affiliated with or endorsed by NIH, NLM or the SEC.
Readout dates are study-reported primary completion dates, which routinely
shift and are not results-release dates. For research and information only —
not investment advice.